Comparative Pharmacology
Head-to-head clinical analysis: PEPCID versus PEPCID RPD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID versus PEPCID RPD.
PEPCID vs PEPCID RPD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion by inhibiting cyclic AMP generation.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
20 mg orally twice daily or 40 mg orally once daily at bedtime for duodenal ulcer; 40 mg orally once daily at bedtime for gastric ulcer; 20 mg orally once daily for GERD; 20 mg orally twice daily for erosive esophagitis; 20 mg intravenously every 12 hours for hospitalized patients with pathological hypersecretory conditions.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in normal renal function; prolonged to 8-10 hours in moderate renal impairment (CrCl 10-50 mL/min) and 15-20 hours in severe impairment (CrCl <10 mL/min); no significant change in hepatic impairment.
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
Renal: ~65-70% unchanged via tubular secretion (active) and glomerular filtration; hepatic metabolism (S-oxidation) ~30%; fecal: <5%.
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist